Clinical Trial Update: Abemaciclib With or Without Atezolizumab for mCRPC [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluates abemaciclib with or without atezolizumab in metastatic castration-resistant prostate cancer, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Tecentriq (atezolizumab)
• VERZENIO (ABEMACICLIB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-02